NVOH is an ETF built almost entirely around Novo Nordisk, and its overall rating suggests it is a generally solid but not risk‑free choice. The fund’s score is driven by Novo Nordisk’s strong financial performance, reasonable valuation, and focus on long-term growth with an attractive dividend, but it is held back somewhat by bearish technical signals, market share pressures, and restructuring challenges. The main risk is the heavy concentration in a single company, which makes the ETF’s performance highly dependent on how Novo Nordisk does.
Positive Factors
Strong Recent Performance
The ETF has shown strong gains over the year and in recent months, indicating solid recent momentum.
Low Expense Ratio
The fund charges a relatively low fee, which helps investors keep more of their returns over time.
Focused Exposure to a Strong Holding
The ETF is heavily invested in Novo Nordisk, which itself has delivered strong year-to-date performance, supporting the fund’s results.
Negative Factors
Extreme Single-Stock Concentration
Nearly all of the fund’s assets are in one company, meaning the ETF’s performance is highly dependent on that single stock.
Sector Concentration in Health Care
With almost all exposure in the health care sector, the fund is vulnerable to downturns or regulatory changes affecting that industry.
Limited Geographic Diversification
The ETF is almost entirely tied to the U.S. market, offering little protection if that market faces a broad decline.
NVOH is an ETF that focuses almost entirely on Novo Nordisk, a major global healthcare and pharmaceutical company known for its diabetes and obesity treatments. It doesn’t track a broad index, but instead gives targeted exposure to this single leader in the health care and pharmaceuticals space, while using a currency hedge to reduce the impact of foreign exchange swings for U.S. investors. Someone might invest for potential growth tied to rising demand for treatments for chronic diseases. The main risk is that the fund is concentrated in one company, so its value can rise or fall sharply with Novo Nordisk’s fortunes.
How much will it cost me?The NVOH ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed funds, as it focuses on a specific company and niche within the healthcare sector, keeping costs relatively modest.
What would affect this ETF?The NVOH ETF could benefit from the growing global demand for innovative healthcare solutions, particularly in diabetes and obesity treatments, areas where Novo Nordisk is a leader. However, potential risks include regulatory changes in the pharmaceutical industry or shifts in healthcare policies that could impact drug pricing and market access. Additionally, while the fund mitigates currency risk, broader economic challenges in Europe or Denmark could still influence its performance.
NVOH Top 10 Holdings
This fund is essentially a one-stock story: Novo Nordisk dominates the portfolio and sets the tone for performance. With the drugmaker’s shares rising in recent months, its strength in diabetes and obesity treatments is doing the heavy lifting for the ETF. There’s no real sector or stock diversification here—it’s a pure health care, pharmaceuticals play, and almost entirely tied to Denmark through this single European giant. If Novo Nordisk keeps climbing, the fund rides high; if it stumbles, the whole ship rocks.
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NVOH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 32.00, equal to the 50-day MA of 28.68, and equal to the 200-day MA of 31.45, indicating a neutral trend. The MACD of 0.93 indicates Positive momentum. The RSI at 53.11 is Neutral, neither overbought nor oversold. The STOCH value of 21.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NVOH.
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―